Advertisement

Germline Genetic Variants Associated with Prostate Cancer and Potential Relevance to Clinical Practice

  • Chee Leng Goh
  • Rosalind Anne EelesEmail author
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 202)

Abstract

The inherited link of prostate cancer predisposition has been supported using data from early epidemiological studies, as well as from familial and twin studies. Early linkage analyses and candidate gene approaches to identify these variants yielded mixed results. Since then, multiple genetic variants associated with prostate cancer susceptibility have now been found from genome-wide association studies (GWAS). Their clinical utility, however, remains unknown. It is recognised that collaborative efforts are needed to ensure adequate sample sizes are available to definitively investigate the genetic–clinical interactions. These could have important implications for public health as well as individualised prostate cancer management strategies. With the costs of genotyping decreasing and direct-to-consumer testing already offered for these common variants, it is envisaged that a lot of attention will be focussed in this area. These results will enable more refined risk stratification which will be important for targeting screening and prevention to higher risk groups. Ascertaining their clinical role remains an important goal for the GWAS community with international consortia now established, pooling efforts and resources to move this field forward.

Keywords

Prostate cancer Genetic variants Genome-wide association studies (GWAS) Clinical application Risk profiling 

Notes

Acknowledgments

This work was funded by the Genetic Associations and Mechanisms in Oncology (GAME-ON) Initiative (NIH ELLIPSE grant: U19CA148537) and CRUK (Cancer Research United Kingdom) C5047/A10692 PRACTICAL grant. We are grateful for the support from The Ronald and Rita McAulay Foundation, The Institute of Cancer Research Everyman Campaign and Prostate Action. We acknowledge support from the NIHR (National Institute for Health Research) to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden Foundation NHS Trust.

Disclosures

RAE is the principal investigator of PRACTICAL and the CEC, and both CLG and RAE are members of the ELLIPSE consortium. RAE has received an honorarium from Succinct Communications and educational grants from Vista Diagnostics, Illumina, Tepnel (now GenProbe) and Janssen-Cilag.

References

  1. Abecasis GR, Auton A, Brooks LD et al (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491:56–65PubMedCrossRefGoogle Scholar
  2. Ahmadiyeh N, Pomerantz MM, Grisanzio C et al (2010) 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci USA 107:9742–9746PubMedCrossRefGoogle Scholar
  3. Akamatsu S, Takata R, Haiman CA et al (2012) Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet 44:426–429PubMedCrossRefGoogle Scholar
  4. Al Olama AA, Kote-Jarai Z, Giles GG et al (2009) Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 41:1058–1060PubMedCrossRefGoogle Scholar
  5. Amin Al Olama AA, Kote-Jarai Z, Schumacher FR et al (2013) A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet 22:408–415Google Scholar
  6. Amundadottir LT, Sulem P, Gudmundsson J et al (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38:652–658PubMedCrossRefGoogle Scholar
  7. Audet-Walsh E, Bellemare J, Nadeau G et al (2011) SRD5A Polymorphisms and Biochemical Failure After Radical Prostatectomy. Eur Urol 60:1226–1234Google Scholar
  8. Bao BY, Pao JB, Huang CN et al (2012) Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy. Int J Cancer 130:876–884PubMedCrossRefGoogle Scholar
  9. Bao BY, Pao JB, Huang CN et al (2011) Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res 17:928–936PubMedCrossRefGoogle Scholar
  10. Barnett GC, Coles CE, Elliott RM et al (2012) Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 13:65–77PubMedCrossRefGoogle Scholar
  11. Barrow PJ, Ingham S, O’Hara C et al (2013) The spectrum of urological malignancy in Lynch syndrome. Fam Cancer 12:57–63PubMedCrossRefGoogle Scholar
  12. Basch E, Oliver TK, Vickers A et al (2012) Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 30:3020–3025PubMedCrossRefGoogle Scholar
  13. Carter BS, Beaty TH, Steinberg GD et al (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 89:3367–3371PubMedCentralPubMedCrossRefGoogle Scholar
  14. Castro E, Goh CL, Olmos D et al (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis and poor survival outcomes in prostate cancer. J Clin Oncol 31:1748–1757Google Scholar
  15. Center MM, Jemal A, Lortet-Tieulent J et al (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079–1092PubMedCrossRefGoogle Scholar
  16. Chang CF, Pao JB, Yu CC, et al (2013) Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy. Ann Surg Oncol 20:2446–2452Google Scholar
  17. Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247–4254PubMedCrossRefGoogle Scholar
  18. Chou R, Croswell JM, Dana T et al (2011) Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155:762–771PubMedCrossRefGoogle Scholar
  19. Chung CC, Magalhaes WC, Gonzalez-Bosquet J et al (2010) Genome-wide association studies in cancer–current and future directions. Carcinogenesis 31:111–120PubMedCrossRefGoogle Scholar
  20. Crawford ED (2003) Epidemiology of prostate cancer. Urology 62:3–12PubMedCrossRefGoogle Scholar
  21. Cui J, Antoniou AC, Dite GS et al (2001) After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am J Hum Genet 68:420–431PubMedCentralPubMedCrossRefGoogle Scholar
  22. Cussenot O, Azzouzi AR, Bantsimba-Malanda G et al (2008) Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer. Clin Cancer Res 14:5635–5639PubMedCrossRefGoogle Scholar
  23. Cybulski C, Huzarski T, Gorski B et al (2004) A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 64:2677–2679PubMedCrossRefGoogle Scholar
  24. Cybulski C, Wokolorczyk D, Huzarski T et al (2006) A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 43:863–866PubMedCrossRefGoogle Scholar
  25. Dluzniewski PJ, Wang MH, Zheng SL et al (2012) Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 21:1774–1782PubMedCentralPubMedCrossRefGoogle Scholar
  26. Duggan D, Zheng SL, Knowlton M et al (2007) Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 99:1836–1844PubMedCrossRefGoogle Scholar
  27. Easton DF (2004) From families to chromosomes: genetic linkage and association studies for finding cancer-predisposition genes. In: Eeles RA, Easton DF, Ponder BA, Eng C (eds) Genetic predisposition to cancer, London, ArnoldGoogle Scholar
  28. Eeles R, Kote-Jarai Z, Guy M, et al (2010) The identification of rare and common variants which predispose to prostate cancer. In: Foulkes WD, Cooney KA (eds) Male reproductive cancers; epidemiology, pathology and genetics, Springer, New YorkGoogle Scholar
  29. Eeles RA, Kote-Jarai Z, Al Olama AA et al (2009) Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 41:1116–1121PubMedCentralPubMedCrossRefGoogle Scholar
  30. Eeles RA, Kote-Jarai Z, Giles GG et al (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316–321PubMedCrossRefGoogle Scholar
  31. Eeles RA, Olama AA, Benlloch S et al (2013) Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 45:385–391PubMedCrossRefGoogle Scholar
  32. Engel C, Loeffler M, Steinke V et al (2012) Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 30:4409–4415PubMedCrossRefGoogle Scholar
  33. Erkko H, Xia B, Nikkila J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316–319PubMedCrossRefGoogle Scholar
  34. Ewing CM, Ray AM, Lange EM et al (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366:141–149PubMedCentralPubMedCrossRefGoogle Scholar
  35. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedCrossRefGoogle Scholar
  36. Fitzgerald LM, Kwon EM, Conomos MP et al (2011) Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 20:1196–1203PubMedCentralPubMedCrossRefGoogle Scholar
  37. Freedman ML, Monteiro AN, Gayther SA et al (2011) Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 43:513–518PubMedCentralPubMedCrossRefGoogle Scholar
  38. Goh CL, Saunders EJ, Leongamornlert DA et al (2013) Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort. BJU Int 112:666–673Google Scholar
  39. Goh CL, Schumacher FR, Easton D et al (2012) Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med 271:353–365PubMedCrossRefGoogle Scholar
  40. Grindedal EM, Moller P, Eeles R et al (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 18:2460–2467PubMedCrossRefGoogle Scholar
  41. Gronberg H, Damber L, Damber JE et al (1997) Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 146:552–557PubMedCrossRefGoogle Scholar
  42. Gudmundsson J, Sulem P, Gudbjartsson DF et al (2009) Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 41:1122–1126PubMedCentralPubMedCrossRefGoogle Scholar
  43. Gudmundsson J, Sulem P, Manolescu A et al (2007a) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39:631–637PubMedCrossRefGoogle Scholar
  44. Gudmundsson J, Sulem P, Rafnar T et al (2008) Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 40:281–283PubMedCentralPubMedCrossRefGoogle Scholar
  45. Gudmundsson J, Sulem P, Steinthorsdottir V et al (2007b) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 39:977–983PubMedCrossRefGoogle Scholar
  46. Haiman CA, Chen GK, Blot WJ et al (2011) Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 43:570–573PubMedCentralPubMedCrossRefGoogle Scholar
  47. Haiman CA, Stram DO, Vickers AJ et al (2013) Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations. J Natl Cancer Inst 105:237–243Google Scholar
  48. Hindroff LA, Junkins HA, Hall PN, et al (2009) A catalog of published genome-wide association studies [Online]. Available www.genome.gov/gwastudies. Accessed March 28 2013
  49. Holt SK, Karyadi DM, Kwon EM et al (2008) Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Cancer Res 14:3823–3831PubMedCentralPubMedCrossRefGoogle Scholar
  50. Houlston RS, Peto J (2004) Genetics and common cancers. In: Ra E, Easton DF, Ponder BA, Eng C (eds) Genetic predisposition to prostate cancer, Arnold, LondonGoogle Scholar
  51. Huang CN, Huang SP, Pao JB et al (2012a) Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol 23:707–713PubMedCrossRefGoogle Scholar
  52. Huang CN, Huang SP, Pao JB et al (2012b) Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. J Intern Med 271:499–509PubMedCrossRefGoogle Scholar
  53. Huang SP, Huang LC, Ting WC et al (2009) Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 18:3068–3074PubMedCrossRefGoogle Scholar
  54. Huang SP, Ting WC, Chen LM et al (2010) Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 17:312–322PubMedCrossRefGoogle Scholar
  55. Jaboin JJ, Hwang M, Lopater Z et al (2011) The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 79:1330–1335PubMedCentralPubMedCrossRefGoogle Scholar
  56. Jemal A, Center MM, Desantis C et al (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893–1907PubMedCrossRefGoogle Scholar
  57. Kader AK, Sun J, Isaacs SD et al (2009) Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 69:1195–1205PubMedCentralPubMedCrossRefGoogle Scholar
  58. Kerns SL, Ostrer H, Stock R et al (2010) Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 78:1292–1300PubMedCentralPubMedCrossRefGoogle Scholar
  59. Kerns SL, Stock R, Stone N et al (2013a) A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 85:e21–e28PubMedCentralPubMedCrossRefGoogle Scholar
  60. Kerns SL, Stone NN, Stock RG et al (2013b) A two-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer. J Urol 190:102–108Google Scholar
  61. Kohli M, Riska SM, Mahoney DW et al (2012) Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc 87:240–246PubMedCrossRefGoogle Scholar
  62. Kote-Jarai Z, Leongamornlert D, Saunders E et al (2011a) BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 105:1230–1234PubMedCentralPubMedCrossRefGoogle Scholar
  63. Kote-Jarai Z, Olama AA, Giles GG et al (2011b) Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 43:785–791PubMedCentralPubMedCrossRefGoogle Scholar
  64. Lange EM (2010) Identification of genetic risk factors for prostate cancer: analytic approaches using hereditary prostate cancer families. In: Foulkes WD, Cooney KA (eds) Male reproductive cancers; epidemilogy, pathology and genetics, Springer, New YorkGoogle Scholar
  65. Larson BT, Magi-Galluzzi C, Casey G et al (2008) Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. J Urol 179:1344–1348PubMedCrossRefGoogle Scholar
  66. Leongamornlert D, Mahmud N, Tymrakiewicz M et al (2012) Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 106:1697–1701PubMedCentralPubMedCrossRefGoogle Scholar
  67. Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85PubMedCrossRefGoogle Scholar
  68. Lindstrom S, Schumacher F, Siddiq A et al (2011) Characterizing associations and SNP–environment interactions for GWAS–identified prostate cancer risk markers–results from BPC3. PLoS ONE 6:e17142PubMedCentralPubMedCrossRefGoogle Scholar
  69. Mac Manus MP, Matthews JP, Wada M et al (2006) Unexpected long-term survival after low-dose palliative radiotherapy for non-small cell lung cancer. Cancer 106:1110–1116PubMedCrossRefGoogle Scholar
  70. Macinnis RJ, Antoniou AC, Eeles RA et al (2011) A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol 35:549–556PubMedGoogle Scholar
  71. Macinnis RJ, Antoniou AC, Eeles RA et al (2010) Prostate cancer segregation analyses using 4390 families from UK and Australian population–based studies. Genet Epidemiol 34:42–50PubMedGoogle Scholar
  72. Maki HE, Waltering KK, Wallen MJ et al (2006) Screening of genetic and expression alterations of SRC1 gene in prostate cancer. Prostate 66:1391–1398PubMedCrossRefGoogle Scholar
  73. Manolio TA (2010) Genomewide association studies and assessment of the risk of disease. N Engl J Med 363:166–176PubMedCrossRefGoogle Scholar
  74. Mitra AV, Bancroft EK, Barbachano Y et al (2011) Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 107:28–39PubMedCrossRefGoogle Scholar
  75. Morote J, del Amo J, Borque A et al (2010) Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J Urol 184:506–511PubMedCrossRefGoogle Scholar
  76. National Institute of Health (2010) ELLIPSE (Elucidating Loci Involved in Prostate Cancer Susceptibility) [Online]. Available http://epi.grants.cancer.gov/pgwas/personnel.html#ellipse. Accessed 1 July 2012
  77. Pashayan N, Duffy SW, Chowdhury S et al (2011) Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 104:1656–1663PubMedCentralPubMedCrossRefGoogle Scholar
  78. Perez CA, Chen H, Shyr Y et al (2010) The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. J Urol 183:2062–2069PubMedCrossRefGoogle Scholar
  79. PRACTICAL (2008) PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) [Online]. Available http://www.srl.cam.ac.uk/consortia/practical/index.html. Accessed 1 July 2012
  80. Schaid DJ (1998) Transmission disequilibrium, family controls, and great expectations. Am J Hum Genet 63:935–941PubMedCentralPubMedCrossRefGoogle Scholar
  81. Schumacher FR, Berndt SI, Siddiq A et al (2011) Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 20:3867–3875PubMedCrossRefGoogle Scholar
  82. Shang Z, Zhu S, Zhang H, et al (2013) Germline homeobox B13 (HOXB13) G84E mutation and prostate cancer risk in european descendants: a meta-analysis of 24 213 cases and 73 631 controls. Eur Urol 64:173–176Google Scholar
  83. Siegel R, Desantis C, Virgo K et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241PubMedCrossRefGoogle Scholar
  84. Sissung TM, Danesi R, Price DK et al (2008) Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 7:19–26PubMedCrossRefGoogle Scholar
  85. Strom SS, Gu Y, Zhang H et al (2004) Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 60:343–351PubMedCrossRefGoogle Scholar
  86. Sun J, Zheng SL, Wiklund F et al (2008) Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 40:1153–1155PubMedCentralPubMedCrossRefGoogle Scholar
  87. Szulkin R, Holmberg E, Stattin P et al (2012) Prostate cancer risk variants are not associated with disease progression. Prostate 72:30–39PubMedCrossRefGoogle Scholar
  88. Takata R, Akamatsu S, Kubo M et al (2010) Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 42:751–754PubMedCrossRefGoogle Scholar
  89. Thomas G, Jacobs KB, Yeager M et al (2008) Multiple loci identified in a genome–wide association study of prostate cancer. Nat Genet 40:310–315PubMedCrossRefGoogle Scholar
  90. Thompson D, Seal S, Schutte M et al (2006) A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev 15:2542–2545PubMedCentralPubMedCrossRefGoogle Scholar
  91. Tischkowitz M, Sabbaghian N, Ray AM et al (2008) Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate 68:675–678PubMedCentralPubMedCrossRefGoogle Scholar
  92. West C, Rosenstein BS, Alsner J et al (2010) Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys 76:1295–1296PubMedCrossRefGoogle Scholar
  93. Whitaker HC, Kote-Jarai Z, Ross-Adams H et al (2010) The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS ONE 5:e13363PubMedCentralPubMedCrossRefGoogle Scholar
  94. Whitman EJ, Pomerantz M, Chen Y et al (2010) Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev 19:1–8PubMedCrossRefGoogle Scholar
  95. Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213PubMedCentralPubMedCrossRefGoogle Scholar
  96. Xu J, Dimitrov L, Chang BL et al (2005) A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 77:219–229PubMedCentralPubMedCrossRefGoogle Scholar
  97. Xu J, Isaacs SD, Sun J et al (2008) Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 14:5819–5824PubMedCentralPubMedCrossRefGoogle Scholar
  98. Xu J, Mo Z, Ye D et al (2012) Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet 44:1231–1235PubMedCrossRefGoogle Scholar
  99. Yang M, Xie W, Mostaghel E et al (2011) SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 29:2565–2573PubMedCrossRefGoogle Scholar
  100. Yeager M, Orr N, Hayes RB et al (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39:645–649PubMedCrossRefGoogle Scholar
  101. Yu CC, Lin VC, Huang CY et al (2013) Prognostic significance of cyclin D1 polymorphisms on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 20 Suppl 3:492–499Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Oncogenetics Team, Division of Cancer Genetics and EpidemiologyThe Institute of Cancer ResearchSuttonUnited Kingdom
  2. 2.Academic Urology and Cancer Genetics UnitsThe Royal Marsden NHS Foundation TrustSuttonUnited Kingdom

Personalised recommendations